target audience: TECH BUYER Publication date: Nov 2024 - Document type: IDC MarketScape - Doc Document number: # US52703324
IDC MarketScape: Worldwide Life Science R&D ITO Services 2024 Vendor Assessment
Content
List of Tables
List of Figures
Get More
When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.
Related Links
Abstract
This IDC study is a refresher of the IDC MarketScape for life science R&D ITO authored in 2021. With a specific focus on life science R&D ITO, this document seeks to compare major IT service providers with each other, based on operational, business, and market-centric criteria that should be important to life science companies when considering the selection of an external service provider to take over IT activities driving digital transformation. IDC MarketScape assessment of IT outsourcing in life science R&D was previously performed in 2011, 2013, 2015, and 2018.
Dr. Nimita Limaye, research VP, Life Science R&D Strategy and Technology, IDC, notes, "The life science industry is in a state of transition. There is an ebb and a flow between the desire to move forward with modernization and the desire to curtail spend owing to significant economic pressures. Cloud strategies are evolving as we speak. AI is being embedded in every aspect of the digital transformation process, fueling a huge unlock for productivity. IT implementation partners are playing a critical role in guiding their customers on the implementation of enterprisewide, AI-enabled digital transformation strategies. Identifying and implementing AI use cases that demonstrate sustainable business value will be key, and this will need to be complemented by business model reinvention to drive success."
"GenAI is redefining the art of the possible for the life science industry. It is personalizing experiences. The ability to provide differentiated patient and provider experiences, powered by AI agents, will distinguish the leaders from the followers in the life science industry."